150
Participants
Start Date
March 1, 2015
Primary Completion Date
August 31, 2018
Study Completion Date
August 31, 2018
7% Hypertonic Saline (HS)
Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
0.9% Isotonic Saline (IS)
Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
Women & Children's Hospital of Buffalo, Buffalo
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, UPenn, Philadelphia
Johns Hopkins University: Pediatric Pulmonary, Baltimore
Nemours Children's Hospital, Orlando
University of Alabama-Birmingham: Pulmonary, Allergy and Critical Care Medicine, Birmingham
Nationwide Children's Hospital, Columbus
Rainbow Babies Children's Hospital and Case Western Reserve University School of Medicine, Cleveland
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children-Indiana U Med Center, Indianapolis
University of Iowa, Department of Pediatrics, Iowa City
Children's Hospital of Wisconsin, Milwaukee
Children's Hospitals and Clinics of Minnesota, Minneapolis
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Washington University School of Medicine, St Louis
Children's Mercy Hospital, Kansas City
Texas Children's Hospital and Baylor College of Medicine, Houston
Children's Hospital of Colorado, Aurora
Stanford University, Palo Alto
Oregon Health Sciences University, Portland
Seattle Children's Hospital, Seattle
Boston Children's Hospital, Boston
University of North Carolina at Chapel Hill, Chapel Hill
British Columbia Children's Hospital, Vancouver
Hospital for Sick Kids, Toronto
Cystic Fibrosis Foundation
OTHER
University of Washington, the Collaborative Health Studies Coordinating Center
OTHER